These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34886931)

  • 1. Population pharmacokinetics of bedaquiline in patients with drug-resistant TB.
    Zhu H; Xie L; Liu ZQ; Wang B; Gao MQ; Lu Y
    Int J Tuberc Lung Dis; 2021 Dec; 25(12):1006-1012. PubMed ID: 34886931
    [No Abstract]   [Full Text] [Related]  

  • 2. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.
    McLeay SC; Vis P; van Heeswijk RP; Green B
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5315-24. PubMed ID: 24957842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
    Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L
    Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.
    Zou J; Chen S; Rao W; Fu L; Zhang J; Liao Y; Zhang Y; Lv N; Deng G; Yang S; Lin L; Li L; Liu S; Qu J
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0081122. PubMed ID: 36106884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
    Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study.
    Keutzer L; Akhondipour Salehabad Y; Davies Forsman L; Simonsson USH
    CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):628-639. PubMed ID: 35102712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients.
    Shao G; Bao Z; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
    Front Pharmacol; 2023; 14():1022090. PubMed ID: 37050904
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation.
    Yang JW; Liao SS; Zhu LQ; Zhao Y; Zhang Y; Sun XY; Rao W; Qu W; Li WZ; Sun LY
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):75-83. PubMed ID: 25207550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
    Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
    Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
    [No Abstract]   [Full Text] [Related]  

  • 19. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
    Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
    Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline for multidrug-resistant TB in paediatric patients.
    Moodliar R; Aksenova V; Frias MVG; van de Logt J; Rossenu S; Birmingham E; Zhuo S; Mao G; Lounis N; Kambili C; Bakare N
    Int J Tuberc Lung Dis; 2021 Sep; 25(9):716-724. PubMed ID: 34802493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.